Key points
- The meta-analysis pooled eight cohorts treated with anti–PD-1 (n = 290), anti–CTLA-4 (n = 175) or both drugs together (n = 51).
- Combination therapy beat anti–PD-1 alone on response rate only in highly immune-infiltrated tumors, not in immune-low ones.
- In immune-high tumors, hypoxia-related pathways were enriched in patients who did not respond to anti–PD-1.
- In mice, adding HIF-2α inhibition to anti–PD-1 controlled immune-rich tumors but not poorly infiltrated ones.
Patients with metastatic melanoma whose tumors are packed with immune cells appear to be the ones who get extra benefit from pairing two immunotherapy drugs, according to a meta-analysis in Science Advances. The researchers found that combined anti–PD-1 and anti–CTLA-4 treatment produced a higher response rate than anti–PD-1 alone only in tumors with high immune infiltration. In immune-low tumors, the combination showed no such advantage.
Immune-checkpoint blockade drugs work by releasing brakes that tumors use to hold back the immune system. Reliable markers for deciding who should get one drug and who should get two have been hard to find, the authors note. Their analysis covered patients given anti–PD-1 (n = 290), anti–CTLA-4 (n = 175) or the combination (n = 51). Every patient had tumor sequencing done before treatment, along with clinical records.
Sorting tumors by how many immune cells they held also exposed different routes to primary resistance. Among immune-high tumors, people who did not respond to anti–PD-1 showed enrichment of pathways tied to hypoxia, meaning low oxygen. Immune-low tumors did not show this pattern. In a separate patient cohort studied with single-cell RNA sequencing, signs of hypoxia went along with more receptor-ligand signaling between tumor cells and the surrounding stromal cells.
As a proof of concept, the team tested this in mice. Blocking HIF-2α, part of the hypoxia pathway and abundant in endothelial cells and fibroblasts, alongside anti–PD-1 controlled tumor growth in models of heavily immune-infiltrated tumors but not in poorly infiltrated ones. The authors say their work shows how grouping tumors by their immune features can point toward new treatment targets.
Why it matters
The authors say reliable biomarkers for choosing between single and combination checkpoint blockade have been hard to find. Measuring immune infiltration could help identify which melanoma patients gain from adding a second drug.
What we don't know yet
The combination-therapy group included 51 patients, and this study tested the HIF-2α combination only in mice, not in patients.
Terms in this story
- Immune-checkpoint blockade
- Treatment with drugs such as anti–PD-1 or anti–CTLA-4 antibodies that switch off molecular brakes on immune cells so they can attack cancer.
- Immune infiltration
- How many immune cells have moved into a tumor.
- Hypoxia
- A condition in which tissue gets too little oxygen.
Sources and verification
DexScience articles are produced with AI assistance and an automated fact-check against the linked sources. Spotted an error? Tell us and we will correct it openly.


